October 13, 2021 -- CARLSBAD, CA - What's the next step in the development of cellular immunotherapies, particularly for liquid and solid tumors? At this week's Cell & Gene Meeting on the Mesa, Dr. Kanya Rajangam, PhD, of Nkarta Therapeutics explained the latest approaches.
ScienceBoard.net caught up to Rajangam, chief medical officer of Nkarta, shortly after a Wednesday plenary session she participated in. She explained Nkarta's approach on allogeneic NK cell therapy, with a particular focus on making these new therapies available more broadly.
NK cells make up about 20% of the normal lymphocytes in the body and are the backbone of Nkarta's technology. The company has leveraged the natural ability of NK cells to target cancer and augmented it with additional functionality to make it a viable cell therapy, Rajangam said.
Learn more by watching the video below.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: